Axogen VP Quackenbush reports initial holdings
Axogen, Inc. Sales VP Doris Quackenbush reported her initial beneficial ownership of company equity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Axogen, Inc. Sales VP Doris Quackenbush reported her initial beneficial ownership of company equity. She directly holds 96,294 shares of common stock, along with multiple employee stock options and restricted stock units that may convert into additional common shares as they vest or become exercisable over time.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Quackenbush Doris
Role
Sales VP
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Employee Stock Option (right to purchase) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Employee Stock Option (right to purchase) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Employee Stock Option (right to purchase) | -- | -- | -- |
| holding | Employee Stock Option (right to purchase) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 65,750 contracts (Direct);
Employee Stock Option (right to purchase) — 43,547 contracts (Direct);
Common Stock — 96,294 shares (Direct)
Footnotes (8)
- F1. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- F2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
- F3. All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vested or will vest each 6 months thereafter.
- F4. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- F5. All underlying options from this grant became fully vested on March 16, 2026.
- F6. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vested or will vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- F7. All underlying options from this grant became fully vested on February 1, 2026.
- F8. All underlying options from this grant became fully vested on March 2, 2024.
Key Figures
Direct common shares: 96,294 shares
Option grant 1: 15,542 shares at $11.88
Option grant 2: 10,285 shares at $8.60
+4 more
7 metrics
Direct common shares
96,294 shares
Common stock beneficially owned directly as of Form 3
Option grant 1
15,542 shares at $11.88
Employee stock option, expiration March 2, 2030
Option grant 2
10,285 shares at $8.60
Employee stock option, expiration February 1, 2032
Option grant 3
5,345 shares at $8.20
Employee stock option, expiration March 16, 2032
RSU grant 1
4,750 units
Restricted Stock Units, fully vesting March 16, 2027
RSU grant 2
38,000 units
Restricted Stock Units, fully vesting March 25, 2029
RSU grant 3
23,000 units
Restricted Stock Units, fully vesting February 26, 2030
Key Terms
Restricted Stock Units, Employee Stock Option (right to purchase), beneficial ownership, vesting schedule, +1 more
5 terms
Restricted Stock Units financial
"All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Option (right to purchase) financial
"All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested"
beneficial ownership financial
"initial beneficial ownership of company equity through common stock, options and restricted stock units"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vesting schedule financial
"based upon a vesting schedule whereby 50% of the aggregate shares vest"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
exercise price financial
"employee stock options list an exercise price such as 11.8800 or 8.6000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Axogen (AXGN) Form 3 filing for Doris Quackenbush show?
The Form 3 shows Sales VP Doris Quackenbush’s initial beneficial ownership in Axogen, including 96,294 common shares held directly plus several employee stock option and restricted stock unit awards that can convert into additional common shares under specified terms and vesting schedules.
What stock options are reported for Doris Quackenbush in the Axogen (AXGN) Form 3?
The filing lists employee stock options over 15,542 shares at $11.88, 10,285 shares at $8.60, and 5,345 shares at $8.20 per share, each expiring between 2030 and 2033, providing potential future rights to acquire Axogen common stock if exercised.
What restricted stock units does Doris Quackenbush hold in Axogen (AXGN)?
Quackenbush holds restricted stock units covering 4,750, 38,000, and 23,000 underlying Axogen common shares. Each restricted stock unit represents a contingent right to receive one share, subject to multi-year vesting schedules described in the footnotes to the Form 3.
When do Doris Quackenbush’s Axogen (AXGN) restricted stock units fully vest?
Footnotes state different RSU grants fully vest on March 16, 2027, March 25, 2029, and February 26, 2030. These vest based on schedules where an initial portion vests after 24 months, with remaining tranches vesting annually until fully vested on the stated dates.
Are Doris Quackenbush’s Axogen (AXGN) stock options already vested?
Footnotes explain that options from certain grants became fully vested on March 2, 2024, February 1, 2026, and March 16, 2026. Fully vested options give her the right, but not the obligation, to purchase Axogen common shares at the specified exercise prices before expiration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
